Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evelyn: Everolimus Beyond Progression in Metastatic Breast Cancer
NCT01773460Phase 3
Key facts
- Status
- Terminated
- Start
- Jul 2013
- Primary completion
- Jul 2014
- Countries
- 1
- Sponsor
- GBG Forschungs
- Modality
- Small Molecules
- Drugs
- everolimus
- Conditions
- breast cancer
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Everolimus + Endocrine Therapy with Placebo + Endocrine Therapy (2 arms). Primary endpoint: Progression Free Survival at 3 years. Started Jul 2013; status: terminated.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Everolimus + Endocrine Therapy
Everolimus combined with a new endocrine therapy partner
Placebo + Endocrine Therapy
Placebo combined with a new endocrine therapy partner
03
Who it enrols
Postmenopausal women with HR+/HER2- metastatic breast cancer who have progressed on prior treatment with exemestane and everolimus.
04
Endpoints
Primary
Progression Free Survival
Secondary
Overall Survival
Clinical Benefit Rate
Chemo-free interval
Safety by toxicity
Compliance
Biological marker
Beyond the preview
Go deeper on NCT01773460.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01773460.